2,898 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Acquired by Bryce Point Capital LLC

Bryce Point Capital LLC bought a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,898 shares of the medical research company’s stock, valued at approximately $535,000.

A number of other large investors have also recently added to or reduced their stakes in CRL. Versant Capital Management Inc raised its position in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after buying an additional 150 shares during the period. Pinnacle Bancorp Inc. grew its stake in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares in the last quarter. Tortoise Investment Management LLC increased its holdings in shares of Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 115 shares during the period. Huntington National Bank lifted its position in shares of Charles River Laboratories International by 120.6% in the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company’s stock worth $55,000 after purchasing an additional 164 shares in the last quarter. Finally, ORG Wealth Partners LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth approximately $56,000. 98.91% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CRL. UBS Group reiterated a “neutral” rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Barclays reduced their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. Bank of America cut their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price on the stock in a research report on Monday, March 3rd. Finally, Morgan Stanley decreased their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $140.79 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $138.70 and a 12-month high of $264.71. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock has a 50-day simple moving average of $163.05 and a 200 day simple moving average of $181.41. The stock has a market capitalization of $7.20 billion, a price-to-earnings ratio of 938.60, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter last year, the firm earned $2.46 EPS. The company’s revenue for the quarter was down 1.1% on a year-over-year basis. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In related news, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the acquisition, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James C. Foster bought 6,075 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).